Proliferative retinopathy is the advanced stage of diabetic retinopathy in which abnormal new blood vessels grow on the surface of the retina. These fragile vessels bleed easily, and the scar tissue they produce can pull the retina away from the back of the eye, potentially causing severe vision loss or blindness. It is the most serious eye complication of diabetes and a leading cause of vision loss worldwide.
How Normal Retinopathy Becomes Proliferative
Diabetic retinopathy progresses through two broad phases. In the earlier, non-proliferative phase, high blood sugar damages the tiny existing blood vessels in the retina. They leak, swell, or close off entirely, starving patches of retinal tissue of oxygen. You might notice no symptoms at all during this stage, or only mild blurriness.
The shift to proliferative retinopathy happens when that oxygen deprivation triggers a distress signal. Starved retinal cells release a protein that stimulates the growth of new blood vessels, a process called neovascularization. In a healthy eye, growing new vessels would be a reasonable repair strategy. In a diabetic eye, these vessels are structurally defective. They sprout along the retinal surface and into the gel-like vitreous cavity of the eye, where they leak blood, ooze fluid, and generate scar tissue. The defining feature that separates proliferative from non-proliferative retinopathy is the presence of these new abnormal vessels, whether on the optic disc, elsewhere on the retina, or evidenced by bleeding into the vitreous.
What It Feels Like
Proliferative retinopathy can develop silently before you notice any change in your vision. When symptoms do appear, they reflect bleeding or scarring inside the eye:
- Floaters: A small bleed from a fragile new vessel releases blood into the vitreous, producing dark spots or streaks that drift across your field of vision.
- Sudden vision loss: A larger bleed can flood the vitreous and block vision almost entirely, sometimes within hours.
- Blank or dark areas: Scar tissue pulling on the retina can create patches of missing vision.
- Blurry or fluctuating vision: Swelling in the central retina (the macula) can make vision shift between clear and blurry from day to day.
- Faded colors and poor night vision: Ongoing retinal damage reduces the eye’s sensitivity to light and color contrast.
Because the early proliferative stage is painless and may not affect central vision right away, many people don’t realize anything is wrong until a significant bleed occurs. This is why regular dilated eye exams matter so much for anyone with diabetes.
How It Causes Blindness
Two complications account for most severe vision loss in proliferative retinopathy: vitreous hemorrhage and tractional retinal detachment.
Vitreous hemorrhage happens when the abnormal vessels rupture and bleed into the clear vitreous gel. A small bleed may clear on its own over weeks, but repeated or heavy bleeding can leave the vitreous permanently clouded. In landmark clinical trials, untreated eyes with high-risk proliferative retinopathy had roughly a 26% chance of severe vision loss within two years.
Tractional retinal detachment is the more dangerous complication. As scar tissue forms around the new blood vessels, it contracts and physically peels the retina away from the tissue underneath. When this traction reaches the macula, the part of the retina responsible for sharp central vision, the damage can be permanent. In some cases, the traction also tears the retina, creating a combined detachment that can worsen rapidly and requires urgent surgery.
How It Is Diagnosed
A dilated eye exam is the starting point. Your eye doctor uses drops to widen the pupil, then examines the retina for signs of new vessel growth, bleeding, or scar tissue.
Fluorescein angiography remains the gold standard for evaluating retinal blood flow. A fluorescent dye is injected into a vein in your arm and photographed as it travels through the retinal vessels. The images reveal leaking vessels, areas of poor blood flow, and new vessel growth that might not be visible during a standard exam. One limitation is that it produces flat, two-dimensional images, which makes it harder to distinguish between shallow and deep layers of the retina.
A newer imaging technique, OCT angiography, creates detailed three-dimensional maps of the retinal blood supply without requiring a dye injection. It can identify certain features like abnormal vessel loops and areas of capillary loss, sometimes even catching early neovascularization that looks indistinguishable from other lesions on traditional angiography. In practice, doctors often use both tests together to get the fullest picture.
Treatment: Injections, Laser, or Surgery
Eye Injections
The most common first-line treatment involves injections of medication directly into the eye. These drugs block the protein that drives abnormal vessel growth, causing existing new vessels to shrink and leak less. Treatment typically begins with three monthly injections, followed by additional injections on an as-needed basis, guided by how the eye responds at follow-up visits.
In clinical comparisons, eyes treated with these injections gained about 3.4 more letters of visual acuity at one year than eyes treated with laser alone. They were also roughly six times more likely to achieve complete regression of abnormal vessels. The injections are particularly helpful when swelling in the macula accompanies the proliferative disease.
Laser Treatment
Panretinal photocoagulation, commonly called scatter laser, has been a mainstay of proliferative retinopathy treatment for decades. The laser burns hundreds of tiny spots across the peripheral retina, deliberately destroying oxygen-starved tissue. This reduces the eye’s demand for new blood vessels and slows or stops their growth. The Diabetic Retinopathy Study showed that laser treatment cut the two-year risk of blindness by about 60% compared to no treatment.
The trade-off is that scatter laser can reduce peripheral vision and night vision, since it sacrifices some retinal tissue to protect central sight. It may also cause mild decreases in color perception. For this reason, many doctors now offer injections as a first option and use laser as a backup or in combination.
Vitrectomy Surgery
When bleeding or scar tissue is too advanced for injections or laser alone, surgery to remove the vitreous gel becomes necessary. The main situations that call for vitrectomy include a vitreous hemorrhage that hasn’t cleared within three to four months, a retinal detachment that threatens the central vision area, a combined tractional and tear-related detachment, or progressive scar tissue growth that continues despite other treatments. Modern vitrectomy techniques achieve functional improvement in 87% or more of cases, a significant advance over earlier surgical results. Recovery typically takes several weeks, during which you may need to maintain a specific head position to help the retina heal.
Blood Sugar Control and Long-Term Outlook
The single most important factor in slowing proliferative retinopathy is blood sugar management. The Diabetes Control and Complications Trial demonstrated that intensive blood sugar control markedly reduces the risk of retinopathy developing or getting worse. There is no threshold below which the risk disappears entirely, meaning that every incremental improvement in blood sugar levels offers some protective benefit. The recommendation from that trial, which remains the standard, is to aim for near-normal blood sugar as early and consistently as possible.
With timely treatment, the prognosis is far better than it was a generation ago. In the Early Treatment Diabetic Retinopathy Study, eyes with early proliferative retinopathy that received prompt treatment had only a 2.6% rate of severe vision loss over five years. Even eyes where treatment was initially deferred and then started later had a low rate of 3.7%. The key variable is catching the disease before a major bleed or detachment occurs, which reinforces why annual or more frequent eye exams are essential for people with diabetes. Once a significant tractional detachment or dense hemorrhage develops, outcomes are less predictable, even with surgery.